Gene therapy for cancer: Is there light at the end of the tunnel?

Journal of the Indian Institute of Science

Volumn 92, Issue 3, 2012, Pages 347-352

  Mulherkar, Rita ^a  

^a ACTREC   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENE THERAPY; CLINICAL TRIAL; GENE DELIVERY; REGULATORY BODIES; TUMOUR CELLS;

DISEASE CONTROL; DISEASES; DRUG THERAPY; EXPERIMENTS; GENE TRANSFER; TUMORS;

GENE THERAPY;

EID: 84876250649     PISSN: 09704140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M et al: Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003, 101(7):2563-2569.
2. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P et al: T lymphocyte-directed gene therapy for ADASCID: initial trial results after 4 years. Science 1995, 270(5235):475-480.
3. Somia N, Verma IM: Gene therapy: trials and tribulations. Nat Rev Genet 2000, 1(2):91-99.
4. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M et al: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348(3):255-256.
5. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I et al: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360(5):447-458.
6. Jia H, Kling J: China offers alternative gateway for experimental drugs. Nat Biotechnol 2006, 24(2):117-118.
7. Mullard A: Gene therapies advance towards finish line. Nat Rev Drug Discov 2011, 10(10):719-720.
8. Miller N: Glybera and the future of gene therapy in the European Union. Nat Rev Drug Discov 2012, 11(5):419.
9. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000, 11(17):2389-2401.
10. Sheridan C: Gene therapy finds its niche. Nat Biotechnol 2011, 29(2):121-128.
11. Tai CK, Kasahara N: Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 2008, 13:3083-3095.
12. Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L et al: Ad3-hTERT-E1 A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. Mol Ther 2012.
13. Creusat G, Rinaldi AS, Weiss E, Elbaghdadi R, Remy JS, Mulherkar R, Zuber G: Proton sponge trick for pH-sensitive disassembly of polyethyleniminebased siRNA delivery systems. Bioconjug Chem 2010, 21(5):994-1002.
14. Conwell CC, Huang L: Recent Advances in Non-viral Gene Delivery. Adv Genet 2005, 53PA:1-18.
15. Loisel-Meyer S, Foley R, Medin JA: Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008, 13:3202-3214.
16. Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12(4):269-281.
17. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
18. Johansson A, Hamzah J, Payne CJ, Ganss R: Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 2012, 109(20):7841-7846.
19. Gardner T, Elzey B, Hahn NM: Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother 2012, 8(4):534-539.
20. Shurin MR, Gregory M, Morris JC, Malyguine AM: Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin Biol Ther 2010, 10(11):1539-1553.
21. Avigan D, Rosenblatt J, Kufe D: Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol 2012, 39(3):287-295.
22. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986, 46(10):5276-5281.
23. Bi WL, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993, 4(6):725-731.
24. Thomas SM, Naresh KN, Wagle AS, Mulherkar R: Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Res 1998, 18(6 A):4393-4398.
25. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993, 53(21):5274-5283.
26. van der Linden RR, Haagmans BL, Mongiat-Artus P, van Doornum GJ, Kraaij R, Kadmon D, Aguilar-Cordova E, Osterhaus AD, van der Kwast TH, Bangma CH: Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 2005, 48(1):153-161.
27. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H: Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007, 15(4):834-840.
28. Schenk E, Essand M, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Danielsson A, Dautzenberg IJ et al: Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 2010, 21(7):807-813.
29. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K et al: Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006, 13(4):716-728.
30. Kothari V, Joshi G, Nama S, Somasundaram K, Mulherkar R: HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer 2010, 126(3):733-742.
31. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M: Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 2012, 118(2):418-427.
32. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK: RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11(1):59-67.
33. Gondi CS, Rao JS: Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 2009, 220(2):285-291.
34. Peng Z: Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005, 16(9):1016-1027.
35. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S et al: Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374(9701):1597-1605.
36. Abbott A: French institute prepares for gene-therapy push. Nature 2012, 481(7382):423-424.